CL2014000863A1 - Una composicion oftalmologica que comprende monooleato de polioxietileno (80) sorbitan, carboximetilcelulosa sodica, glicerina, acido borico, polimero reticulado de acrilatos/acrilato de alquilo c10-30, aceite de ricino, eritritol, levocarnitina, hidroxido de sodio y agua; y su uso para tratar, mitigar o prevenir el sindrome del ojo seco. - Google Patents

Una composicion oftalmologica que comprende monooleato de polioxietileno (80) sorbitan, carboximetilcelulosa sodica, glicerina, acido borico, polimero reticulado de acrilatos/acrilato de alquilo c10-30, aceite de ricino, eritritol, levocarnitina, hidroxido de sodio y agua; y su uso para tratar, mitigar o prevenir el sindrome del ojo seco.

Info

Publication number
CL2014000863A1
CL2014000863A1 CL2014000863A CL2014000863A CL2014000863A1 CL 2014000863 A1 CL2014000863 A1 CL 2014000863A1 CL 2014000863 A CL2014000863 A CL 2014000863A CL 2014000863 A CL2014000863 A CL 2014000863A CL 2014000863 A1 CL2014000863 A1 CL 2014000863A1
Authority
CL
Chile
Prior art keywords
levocarnitine
erythritol
sorbitan
mitigate
glycerin
Prior art date
Application number
CL2014000863A
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47040830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000863(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2014000863A1 publication Critical patent/CL2014000863A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/745Polymers of hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/22Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2014000863A 2011-10-06 2014-04-07 Una composicion oftalmologica que comprende monooleato de polioxietileno (80) sorbitan, carboximetilcelulosa sodica, glicerina, acido borico, polimero reticulado de acrilatos/acrilato de alquilo c10-30, aceite de ricino, eritritol, levocarnitina, hidroxido de sodio y agua; y su uso para tratar, mitigar o prevenir el sindrome del ojo seco. CL2014000863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161544151P 2011-10-06 2011-10-06

Publications (1)

Publication Number Publication Date
CL2014000863A1 true CL2014000863A1 (es) 2014-08-29

Family

ID=47040830

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000863A CL2014000863A1 (es) 2011-10-06 2014-04-07 Una composicion oftalmologica que comprende monooleato de polioxietileno (80) sorbitan, carboximetilcelulosa sodica, glicerina, acido borico, polimero reticulado de acrilatos/acrilato de alquilo c10-30, aceite de ricino, eritritol, levocarnitina, hidroxido de sodio y agua; y su uso para tratar, mitigar o prevenir el sindrome del ojo seco.

Country Status (17)

Country Link
US (7) US8957048B2 (es)
EP (1) EP2765987A1 (es)
JP (1) JP6209163B2 (es)
CN (2) CN103974694A (es)
AU (1) AU2012318556B2 (es)
BR (1) BR112014008314B1 (es)
CA (1) CA2851398C (es)
CL (1) CL2014000863A1 (es)
HK (1) HK1201042A1 (es)
IL (1) IL231970A (es)
MX (1) MX2014004203A (es)
MY (1) MY169328A (es)
RU (1) RU2651046C2 (es)
SG (1) SG11201401323PA (es)
TW (1) TWI642432B (es)
WO (1) WO2013052760A1 (es)
ZA (1) ZA201404121B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PT2787968T (pt) * 2011-12-07 2020-06-16 Allergan Inc Administração eficaz de lípidos ao filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
WO2016085885A1 (en) * 2014-11-25 2016-06-02 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
CN107106325B (zh) 2015-01-12 2021-05-25 科达莱昂治疗公司 微滴递送设备和方法
JP2018515153A (ja) 2015-04-10 2018-06-14 ケダリオン セラピューティックス,インコーポレイテッド 交換式アンプルを備えた圧電式ディスペンサ
CN105311042B (zh) * 2015-09-07 2019-04-12 广州国宇医药科技有限公司 一种糖醇组合物在制备治疗干眼症的药物中的应用
EP3397136A4 (en) 2015-12-28 2019-11-06 Indiana University Research & Technology Corporation IDENTIFICATION OF CONTACT LENS HOLDERS PREDISPOSED TO INCONFORT FROM CONTACT LENSES
CA3032695C (en) 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
KR102550534B1 (ko) 2017-01-20 2023-07-03 노파르티스 아게 압전 유체 분배기
CN114376961A (zh) * 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
JP7150282B2 (ja) * 2017-09-14 2022-10-11 協同乳業株式会社 涙液分泌能・涙液安定性を改善するための飲食品または製剤
JP7436363B2 (ja) 2017-12-08 2024-02-21 ノバルティス アーゲー 流体送達アライメントシステム
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
BR112022020948A2 (pt) 2020-04-17 2023-04-11 Kedallion Therapeutics Inc Sistema de distribuição livre de conservantes hidrodinamicamente atuado
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2022103775A1 (en) 2020-11-12 2022-05-19 Singletto Inc. Microbial disinfection for personal protection equipment
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
CN114533582B (zh) * 2022-02-25 2023-05-09 北京协和生物工程研究所有限公司 一种包含多种渗透压保护剂的眼周用组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
WO1991001718A1 (fr) 1989-08-03 1991-02-21 Eisai Co., Ltd. Procede de photostabilisation pour collyre liquide et collyre liquide photostabilise
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
DE19859910C2 (de) 1998-12-23 2001-03-22 Ratiopharm Gmbh Orales Arzneimittel
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
CN1441679A (zh) 2000-07-14 2003-09-10 阿勒根公司 包含具有提高的溶解度的治疗活性组分的组合物
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4084997B2 (ja) 2000-11-08 2008-04-30 エフエックスエス・ベンチャーズ・エルエルシー 防腐剤増強剤として単純糖類を含有する改良眼科用およびコンタクトレンズ用溶液
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
EP1611883A1 (en) 2003-03-26 2006-01-04 Menicon Co., Ltd. Composition for ophthalmic use
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
MX2009009207A (es) * 2007-02-28 2010-02-12 Aciex Therapeutics Inc Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
CA2741288A1 (en) 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
CN102458430A (zh) * 2009-06-05 2012-05-16 阿勒根公司 人工泪液及治疗用途
MY160388A (en) 2009-10-07 2017-03-15 Kerecis Ehf A scaffold material for wound care and/or other tissue healing applications
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PT2787968T (pt) * 2011-12-07 2020-06-16 Allergan Inc Administração eficaz de lípidos ao filme lacrimal humano utilizando um sistema de emulsão sensível ao sal

Also Published As

Publication number Publication date
SG11201401323PA (en) 2014-08-28
TW201316984A (zh) 2013-05-01
NZ625799A (en) 2016-09-30
US20130090308A1 (en) 2013-04-11
US10105386B2 (en) 2018-10-23
US20140242022A1 (en) 2014-08-28
IL231970A (en) 2016-12-29
JP6209163B2 (ja) 2017-10-04
TWI642432B (zh) 2018-12-01
US8957048B2 (en) 2015-02-17
HK1201042A1 (en) 2015-08-21
IL231970A0 (en) 2014-05-28
CN108175778A (zh) 2018-06-19
CA2851398A1 (en) 2013-04-11
US20220096523A1 (en) 2022-03-31
BR112014008314B1 (pt) 2022-04-05
MX2014004203A (es) 2014-10-17
EP2765987A1 (en) 2014-08-20
JP2014528452A (ja) 2014-10-27
MY169328A (en) 2019-03-21
RU2014122945A (ru) 2015-12-20
AU2012318556A1 (en) 2014-07-31
US20150196582A1 (en) 2015-07-16
WO2013052760A1 (en) 2013-04-11
RU2651046C2 (ru) 2018-04-18
US20210000859A1 (en) 2021-01-07
CA2851398C (en) 2019-11-05
CN103974694A (zh) 2014-08-06
AU2012318556B2 (en) 2017-10-26
ZA201404121B (en) 2016-07-27
US20190247419A1 (en) 2019-08-15
BR112014008314A2 (pt) 2017-04-11
US20240122963A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
CL2014000863A1 (es) Una composicion oftalmologica que comprende monooleato de polioxietileno (80) sorbitan, carboximetilcelulosa sodica, glicerina, acido borico, polimero reticulado de acrilatos/acrilato de alquilo c10-30, aceite de ricino, eritritol, levocarnitina, hidroxido de sodio y agua; y su uso para tratar, mitigar o prevenir el sindrome del ojo seco.
PE20180230A1 (es) Composicion hemostatica y dispositivo hemostatico (variantes)
CL2013000603A1 (es) Compuestos derivados de quinolina y quinoxalina, inhibidores pi3k; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, nocicenociceptiva y oftalmica.
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
BR112014016505A8 (pt) conjunto e sistema de tratamento para síndrome do olho seco
CL2014002730A1 (es) Estructuras unitarias absorbentes que comprenden un núcleo absorbente y/o una capa de absorción y dispersión para artículos absorbentes.
CL2014002087A1 (es) Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal.
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
CR20140541A (es) Formulaciones farmacéuticas tópicas no acuosas
BR112013021509A2 (pt) composições para cuidado pessoal
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
BR112014011067A2 (pt) proteção absorvente descartável
BR112017018143A2 (pt) dispositivo dispensador para receber um rolo de papel toalha ou de material em folha de aspecto tecidual
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
MX2014012942A (es) Dialisato a base de polimero.
PH12016501168A1 (en) Bicalutamide analogs or (s)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
BR112017002354A2 (pt) artigo absorvente extensível
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
BR112014002372A2 (pt) recuperação de petróleo
CL2013001313A1 (es) Composicion que comprende microorganismos probióticos no replicantes para prevenir o tratar infecciones gastrointestinales
BR112015015348A2 (pt) materiais e métodos
BR102013030668A8 (pt) Composição para a preparação de ácido hialurônico reticulado viscoelástico e ácido hialurônico reticulado obtido por meio da utilização da mesma
CL2014000509A1 (es) Co-cristales que comprenden ciprodinil y ditianon; proceso para preparar los co-cristales; composicion para la proteccion de cultivos que comprende dichos co-cristales; uso para combatir hobgos fitopatógenos.